Financials in USD. Standardized financial statements.
A compact view of how Prime Medicine, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $4.63M | $2.98M | $0 | $0 | $0 | $5.21M | $0 |
| Revenue Growth? | +55.3% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% |
| Cost of Revenue? | $7.32M | $0 | $0 | $0 | $0 | $2.98M | $2.76M |
| Gross Profit? | -$2.69M | $2.98M | $0 | $0 | $0 | $2.23M | -$2.76M |
| Gross Margin? | -58.1% | +100.0% | 0.0% | 0.0% | 0.0% | +42.8% | 0.0% |
| Operating Expenses? | $205.66M | $205.45M | $204.79M | $116.54M | $84.47M | $3.16M | $2.17M |
| Operating Income? | -$208.35M | -$202.47M | -$204.79M | -$116.54M | -$84.47M | -$932,000 | -$2.17M |
| EBITDA? | -$195.76M | -$196.34M | -$186.64M | -$114.32M | -$83.91M | -$889,000 | -$2.17M |
| Income Before Tax | -$201.14M | -$195.88M | -$198.41M | -$122.77M | -$165.85M | -$1.54M | -$2.52M |
| Income Tax Expense | $0 | $0 | -$279,000 | -$948,000 | -$486,000 | $1.87M | $4,000 |
| Net Income? | -$201.14M | -$195.88M | -$198.13M | -$121.82M | -$165.37M | -$3.41M | -$2.53M |
| EPS? | $-1.35 | $-1.65 | $-2.18 | $-1.46 | $-1.92 | $-0.05 | $-0.03 |
| Diluted EPS? | $-1.35 | $-1.65 | $-2.18 | $-1.46 | $-1.92 | $-0.05 | $-0.03 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality